Imidazole: A selective inhibitor of thromboxane synthetase

Salvador Moncada*, Stuart Bunting, Kevin Mullane, Peter Thorogood, John R. Vane, Amiram Raz, Philip Needleman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

252 Scopus citations

Abstract

Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes (IC50: 22 μg/ml; determined by bioassay). The inhibitor is selective, for prostaglandin cyclo-oxygenase is only affected at high doses. Radiochemical data confirms that imidazole blocks the formation of 14C-thromboxane B2 from 14C-PHG2. Several imidazole analogues and other substances were tested but only 1-methyl-imidadole was more potent that imidazole iteself. The use of imidazole of inhibit thromboxane formation could help to elucidate the role of thromboxanes in physiology or pathophysiology.

Original languageEnglish
Pages (from-to)611-618
Number of pages8
JournalProstaglandins
Volume13
Issue number4
DOIs
StatePublished - Apr 1977
Externally publishedYes

Funding

FundersFunder number
National Institutes of HealthSCOR HL-17646, HE-14397

    Fingerprint

    Dive into the research topics of 'Imidazole: A selective inhibitor of thromboxane synthetase'. Together they form a unique fingerprint.

    Cite this